- Home
- / NuCana
NuCana
Stock Price
$1.8
2024-10-29
Market Capitalization
$3.9 M
2024-10-29
NuCana Summary
Company Summary
- Overview
- NuCana is a clinical-stage biopharmaceutical company developing new medicines to treat cancer. It offers ProTide technology, specific combinations of aryl, ester, and amino acid groups (phosphoramidate motifs) that protect the activated nucleotide analog. The ProTide candidates include Acelarin, NUC-3373, and NUC-7738.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Edinburgh, GB | view all locations
- Website
- http://www.nucana.com
- Cybersecurity rating
Table of Contents
Key People
Don Munoz, Chief Financial Officer
Jeffrey Bloss, Chief Medical Officer
Theresa Bruce, Senior VP Clinical Operations
LocationsView all
3 locations detected
Edinburgh, Scotland HQ
United Kingdom
3 Lochside Way
Newton, MA
United States
Riverside Center, 275 Grove St, Auburndale
London, England
United Kingdom
77 Cannon St
NuCana Financials
Summary Financials
- Gross profit (FY, 2025)
- £1.9M
- Net income (FY, 2025)
- (£29.4M)
- Cash (FY, 2025)
- £24.3M
- EBIT (FY, 2025)
- (£18.1M)
- Enterprise value
- ($19.6M)